|
KMID : 0882420070720050446
|
|
Korean Journal of Medicine
2007 Volume.72 No. 5 p.446 ~ p.450
|
|
|
New and emerging drugs in type 2 diabetes
|
|
Park Ie-Byung
|
|
|
Abstract
|
|
|
Recent advances in understanding insulin secretion, action and signaling have led to the development of new
pharmacological agents. Several new emerging drugs and drug classes for the management of diabetes are under
development, including the incretin mimetic agents (exenatide, dipeptidyl peptidase 4 inhibitors, and glucagon-like
peptide 1 analogues), the amylin analogue pramlintide, the cannabinoid-1 receptor antagonist rimonabant, the mixed
peroxisome proliferator-activated receptor agonists muraglitazar and the inhaled insulin preparation Exubera. New drugs
and technologic advances being made available will help achieve the goals of treating patients with diabetes to all the
appropriate metabolic targets. Longer term studies will help providers weigh the benefits, adverse effects, cost, and
unknown long-term risks of these medications.(Korean J Med 72:446-450, 2007)
|
|
|
KEYWORD
|
|
|
Incretin, Exenatide, DPP-IV inhibitor, Pramlintide, Rimonabant, Inhaled insulin
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|